Bio-View Ltd

Bio-View Ltd Share · IL0010960495 (XTAE) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Bio-View Ltd
No Price
Closing Price XTAE 01.05.2026: 16,00 ILA
01.05.2026 10:44
Current Prices from Bio-View Ltd
ExchangeTickerCurrencyLast TradePriceDaily Change
XTAE: TASE
TASE
BIOV.TA
ILA
01.05.2026 10:44
16,00 ILA
-0,40 ILA
-2,44 %
Share Float & Liquidity
Free Float 48,03 %
Shares Float 66,76 M
Shares Outstanding 138,99 M
Company Profile for Bio-View Ltd Share
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. Its products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation with advanced review and analysis tools; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 2000 and is headquartered in Rehovot, Israel.

Company Data

Name Bio-View Ltd
Company Bio-View Ltd
Website https://www.bioview.com
Primary Exchange XTAE TASE
ISIN IL0010960495
Asset Class Share
Sector Healthcare
Industry Medical - Devices
CEO Daniel Klain
Market Capitalization 22 Mio
Country Israel
Currency ILA
Employees 0,0 T
Address 3 Pekeris Street, 7670203 Rehovot
IPO Date 2006-03-12
Dividends from 'Bio-View Ltd'
Ex-Date Dividend per Share
22.03.2017 20,00 ILA

Stock Splits

Date Split
24.12.2023 10:1

Ticker Symbols

Name Symbol
TASE BIOV.TA
More Shares
Investors who hold Bio-View Ltd also have the following shares in their portfolio:
HEIWA CORP
HEIWA CORP Share
ISHARES MSCI JAPAN VALUE ETF
ISHARES MSCI JAPAN VALUE ETF ETF